Instinctif Partners Life Sciences’ Clients Shortlisted for OBN and Scrip 2015 Industry Awards
29 September 2015, London, Manchester: Instinctif Partners Life Science supports its clients with entries to awards and is delighted that this month its clients have been shortlisted for a number of Awards including the OBN 2015 Awards and the 2015 Scrip Awards.
During August, OBN, the biotech trade association, announced that six of Instinctif Partners’ clients were represented across five categories. These included Atopix Therapeutics, Astex Pharmaceuticals, Immunocore, Oxford Gene Technology, Crescendo Biologics and Imperial Innovations.
Atopix Therapeutics, clinical stage biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma has been shortlisted for the Best Emerging Biotech
Two oncology focused clients are nominated for Best Biotech Dealmaker: Astex Pharmaceuticals, a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system; Immunocore, with a highly innovative immuno-oncology platform technology called ImmTACs which have the potential to treat diseases with high unmet medical need including cancer, viral infections and autoimmune diseases.
Oxford Gene Technology, a company that provides world-class genetics research solutions to leading clinical and academic research institutions, has been shortlisted for Best Medtech Dealmaker
Crescendo Biologics, a company that is developing innovative new medicines based on its single domain antibody fragment technology, has been shortlisted for Best Emerging Biotech Fundraiser
Imperial Innovations, a technology commercialisation company, combining the activities of technology transfer, intellectual property licensing and protection, company incubation and investment has been shortlisted for the Highest Impact Investor.
Winners of the OBN 2015 Awards will be announced at the OBN Gala Dinner on 2nd October.
This year’s Scrip Awards finalists were announced in September, with three of Instinctif Partners’ clients represented in four categories.These included Clinigen, Ablynx and Immunocore.
Clinigen, a rapidly-growing specialty pharmaceutical and services company with a unique business model dedicated to delivering the right drug to the right patient at the right time to improve the quality of people’s lives around the world has been shortlisted in two categories; Financing Deal of the Year and Management Team of the Year.
Belgian biopharmaceutical company, Ablynx, which is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments is a finalist in the Clinical Advance of the Year Award for its Phase II TITAN trial of caplacizumab in acquired thrombotic thrombocytopenic purpura.
The Biotech Company of the Year Award category sees Immunocore as a shortlisted finalist.
Winners of the 2015 Scrip Awards will be announced at the 11th Annual Scrip Awards Dinner on 2nd December.
For further information about the OBN Awards click here and for the Scrip Awards please click here.